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Abstract - 202 
Background: Uncertainty surrounds why hepatitis C virus (HCV) is concentrated amongst 
HIV-positive men who have sex with men (MSM). We used mathematical modelling to 
explore reasons for these infection patterns, and implications for HCV treatment-as-
prevention.  
Methods: Using a joint MSM HIV/HCV transmission model parameterised with UK 
behavioural data, we considered how biological (heightened HCV infectivity and reduced 
spontaneous clearance among HIV-positive MSM) and/or behavioural factors (preferential 
sexual mixing by HIV-status and risk heterogeneity) could concentrate HCV infection in HIV-
positive MSM similar to commonly observed (5-20 times the HCV prevalence in HIV-
negative MSM; defined as the HCV-ratio).  We explored HCV treatment-as-prevention 
impact under differing HCV-ratios. 
Results: Biological factors produced low HCV-ratios (<3), not explaining the skewed 
epidemic. However, combining preferential mixing by HIV-status with sexual risk behaviour 
heterogeneity produced high HCV-ratios (>10) that were highly sensitive to both factors. 
Irrespective of the HCV-ratio or behavioural/biological factors, HCV treatment of HIV-
diagnosed MSM markedly reduced HCV prevalence among HIV-positive MSM, but less 
impact was achieved among all MSM for lower HCV-ratios. 
Conclusion: Sexual behaviour patterns likely drive observed HCV infection patterns among 
HIV-positive MSM. Changes in these patterns could disseminate HCV amongst HIV-negative 
MSM, limiting the impact of targeting HCV treatment to HIV-diagnosed MSM. 
Key words: hepatitis C virus, HIV, men who have sex with men, antiviral treatment, 
prevention 
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Key messages 
Biological factors alone do not explain why the HCV epidemic has been strongly 
concentrated among HIV-positive MSM;  
Sexual behavioural risk heterogeneity and HIV preferential mixing amongst sexual partners 
is likely to explain this observation. Changes in sexual mixing patterns could reshape the 
epidemic. 
Targeted HCV treatment-as-prevention amongst HIV-diagnosed MSM could be an 
important tool for combating the current HCV epidemic, but will have less impact in 
settings which have, or develop, a substantial burden of HCV among HIV-negative MSM, 
underscoring the importance of monitoring in this population.  
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Introduction 
An epidemic of hepatitis C virus (HCV) continues unfolding amongst HIV positive men-who-
have-sex-with-men (MSM) in the UK, Europe, the US and Australia[1]. HCV is a leading non-
AIDS cause of death among MSM with HIV[2]. The incidence of HCV among HIV-positive 
MSM is generally 5-20 times higher than HIV-negative MSM[1, 3]. In the UK, HCV 
seroprevalence among HIV-negative MSM was estimated to be 1.2% (0.6-2.1%) in 2009[4], 
but was 9.9% amongst HIV-positive MSM in 2012[5]. 
Behavioural and biological factors have been proposed to account for the large discrepancy 
in HCV burden between HIV-positive and HIV-negative MSM.[6, 7] Biological factors include 
reduced chances of spontaneously clearing the HCV virus[8, 9] and higher HCV viral loads, 
potentially leading to greater infectivity in HIV-positive MSM[10, 11]. 
Behavioural factors include sexual partner selection based on HIV status and heterogeneity 
in sexual risk[6, 12]. Heterogeneities in risk and precautionary behaviours could incorporate 
differences in numbers of sexual partners and use of condoms, different preferences for 
ano-brachial insertion (fisting) and injecting illicit drugs[6, 13-15]. Additionally, partner 
selection and risk behaviours may interact, such as reduced condom use occurring between 
couples that assume they are sero-concordant[12]. These heterogeneities in sexual risk and 
mixing could lead to groups with higher-risk, and thus greater sexually transmitted infection 
(STI) and HIV prevalences. 
We developed a dynamic joint HIV/HCV transmission model among MSM to explore the 
contribution of behavioural and biological factors to why HCV is concentrated among HIV-
positive MSM. We assessed how variations in these biological and behavioural factors’ may 
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affect the HCV distribution, and evaluated the resulting implications for HCV treatment-as-
prevention[16].  
 
Methods 
Model Derivation 
A dynamic, deterministic model of HIV and HCV transmission among MSM was developed. 
We divided MSM into compartments (model schematic in supplementary figure S1) defined 
by HIV status (susceptible, undiagnosed acute infection, undiagnosed chronic infection and 
diagnosed HIV infection), HCV status (susceptible, chronic HCV, chronic HCV treatment 
failure) and low and high sexual risk groups, based on annual numbers of partners that MSM 
have anal sex with. A simplified model was designed, that was not intended to rigorously 
simulate the historical HIV epidemic as done in other studies[17]. 
MSM enter the model when they reach sexual maturity and exit though death or ageing out 
the model at 65 years of age. The model is dynamic, such that the risk of an individual 
acquiring HIV or HCV is related to the background prevalence of that infection, which can 
change over time. We assume both diseases are transmitted through sexual episodes, which 
may involve unprotected anal intercourse, injecting drug use and fisting[18-21]. Because 
individuals with more anal intercourse partners (whom we deem ‘high-risk’) also have a 
higher frequency of injecting drugs, fisting, and other high-risk behaviours, high-risk MSM 
were assumed to have higher chances of HIV and HCV exposure[6, 13-15].  
Once HIV infected, individuals enter undiagnosed acute HIV infection, with heightened HIV 
infectivity[22], subsequently transitioning to undiagnosed chronic HIV infection. Individuals 
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are assumed to not become HIV diagnosed during the short (2.6 months) acute phase of HIV 
infection[22].  On diagnosis, MSM transition to diagnosed chronic HIV, where a proportion 
receive HIV antiretroviral treatment (ART) which we assume reduces HIV infectivity[23, 24] 
and increases survival[25, 26].  
Newly HCV-infected MSM that don’t spontaneously clear HCV transition to chronic HCV. The 
HCV acute phase was not included due to its likely small contribution to HCV 
transmission[27]. Those clearing HCV remain susceptible. When included in our analysis, 
HCV treatment is assumed to cure infection for a proportion of individuals but not confer 
immunity. Successfully treated MSM remain at risk of reinfection. Unsuccessfully treated 
MSM move into the treatment failure class and remain infected with HCV.  
To explore the implications of HIV infection on HCV infection/transmission patterns, we 
consider scenarios where HIV has no effect on HCV and the alternative; where HIV infection 
increases HCV liver-related progression and mortality[28], reduces spontaneous 
clearance[8, 9] and increases HCV infectivity[10, 11]. We assume HCV does not impact on 
HIV disease progression or ART response[25].  
 
Model Parameterization  
We modelled HIV and HCV transmission among sexually active MSM aged 15-65, 
parameterizing sexual behaviour with the UK component of the European MSM Internet 
Survey (EMIS-UK)[29]. EMIS was an online survey undertaken during June-August 2010, 
recruiting online and promoted offline through print media. Over 18,000 MSM living in the 
UK participated. From EMIS-UK data, we calculated the proportion of HIV-diagnosed MSM’s 
8 
 
sexual partners they assumed were HIV-positive (36.2%) and condom use in these pairings 
(13.0% in last sex act) compared to (68.0% in last sex act) other MSM partnerships. EMIS-UK 
data also determined the heterogeneity in frequencies of casual sexual partnerships. When 
risk heterogeneity was explored, we divided the MSM population into categories of low and 
high-risk by the annual number of sexual partnerships, 14 or less and 15 or greater, 
respectively, with 82.2% and 17.8% in the low and high-risk groups, respectively. In some 
scenarios, an additional risk was also associated with MSM in the high-risk group due to 
EMIS-UK data suggesting a greater proportion of these MSM either inject drugs (3.6% versus 
1.0% amongst low-risk MSM), or undertake receptive (21.1% versus 8.6%) or insertive fisting 
(38.7% versus 14.0%) in the last year[6, 13-15]. Biological parameters were obtained from 
the literature. HCV treatment was not included in the baseline model because we were not 
aiming to closely model the precise HCV epidemic in the UK, and it was not considered to be 
an important determinant of observed epidemic patterns at existing treatment rates[5].  
All model parameters are outlined in Tables 1 and 2. 
 
Model fitting and scenarios 
For each different behavioural and biological risk factor scenario (detailed below), the 
model was calibrated to a stable HIV and HCV prevalence. The model was run with a non-
least squares fitting algorithm which took point values of all parameters relevant to the 
scenario (shown in Table 2), except the transmission parameters for HCV and HIV which 
were used to fit the simulation. We calibrated the model to a 5% HIV prevalence among 
MSM[30] and a chronic HCV prevalence of 10% amongst HIV-infected MSM[16]. This 
approach gives a simplified characterisation of the HIV and HCV epidemic among MSM in 
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the UK. We did not fit the HCV prevalence amongst HIV-uninfected MSM. However, we 
explored several scenarios involving the inclusion of various biological and behavioural 
factors to see how they affected the HCV prevalence amongst HIV-uninfected MSM, while 
for each scenario assuming a 10% HCV prevalence amongst HIV-infected MSM: 
1. Baseline: No effect of HIV infection on HCV progression, transmissibility or 
spontaneous clearance; no heterogeneity in sexual risk behaviour or HIV preferential 
mixing among MSM. 
2. Biological factors only: Infection with HIV reduces HCV spontaneous clearance 
probability, increases HCV-related mortality, and increases HCV infectivity. 
3. Mixing by HIV status with biological factors: MSM select partners preferentially 
based on HIV status with errors in judgement, with an additional sub-scenario 
assuming less condom usage among partnerships where HIV-diagnosed individuals 
think their partner is also HIV-positive (irrespective of whether right or not). 
Biological factors included as above. 
4. Heterogeneity in sexual risk behaviour with biological factors: Heterogeneity in 
sexual risk behaviour based on number of casual partners. Two additional sub-
scenarios further assume that a) MSM select partners preferentially based on risk 
group, or b) MSM select partners preferentially based on risk and assume further 
elevated transmission risk associated with high-risk MSM based on their higher 
prevalence of injecting drugs and fisting. Biological factors included as above. 
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5. All factors: Mixing by HIV status and heterogeneity in sexual risk included as 
described above with all associated effects from previous scenarios. Biological 
factors included as above. 
 
Model analyses and sensitivity analyses 
Impact on the HCV ratio: To explore the impact of these scenarios on the HCV relative 
burden among HIV-positive MSM, we define the “HCV ratio” as the chronic prevalence of 
HCV in HIV-positive MSM divided by the chronic prevalence of HCV in HIV-negative MSM. 
We firstly use point values for each parameter (Table 2) and assess whether each scenario 
produces a HCV ratio commonly observed in the UK and other settings (HCV ratio >5)[1, 3, 4, 
16]. Then, to test the model’s sensitivity to parameter variation, for scenario 5 (All factors 
included), we undertook a univariate sensitivity analysis where we varied each parameter 
individually across +/-100% of their point value, and assessed the effect on the HCV ratio. 
These wide parameter uncertainty ranges were used to account for unknown biases and 
uncertainties in the data, with the same range being assumed for each parameter to see 
how each affected the results over the same relative range. We then performed bivariate 
sensitivity analyses on key parameters identified at the univariate level, quantifying their 
importance for three different levels of error in judgement of HIV status of sexual partners (-
100%, 0% and +100% of point value). 
Impact on HCV treatment-as-prevention initiatives: We explored the impact of HCV 
treatment-as-prevention for the different scenarios (Table 2). For each, we assessed the 10-
year decrease in chronic HCV prevalence amongst HIV-positive MSM and all MSM achieved 
for an illustrative HCV treatment intervention that annually treated 10% of HIV-diagnosed 
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HCV co-infected MSM. We assumed a 90% sustained viral response (SVR) with interferon-
free direct acting antiviral therapy (DAA)[31]. By simultaneously sampling (5000 Iterations) 
all the parameters varied for the univariate sensitivity analysis undertaken on scenario 5, we 
then considered the effect of variations in the HCV ratio on the impact of the illustrative 
HCV treatment-as-prevention strategy. Lastly, for scenario 5 (All factors), we individually 
varied key parameters across +/-100% of the point value to assess their influence on the 
reduction in chronic HCV prevalence achieved with treatment.  
 
Results 
HCV Ratio Analysis 
Model projections of the HCV ratio for the different scenarios in Table 2 are shown in Figure 
1. If no biological or behavioural factors are included (Scenario 1), the predicted HCV ratio is 
low but greater than one (1.39) due to MSM entering the model being susceptible to both 
diseases, so creating an increased proportion of HIV-negative MSM without HCV. Including 
biological factors only (Scenario 2) marginally elevates the HCV ratio (1.41) because the 
greater HCV transmissibility in HIV-HCV co-infected MSM increases HCV transmission in 
both HIV-negative and positive MSM. Similarly, including preferential mixing by HIV status 
(Scenario 3) cannot reproduce the high HCV ratio observed in the UK (HCV ratio of 5-20), 
with modelling projecting an HCV ratio of 1.7, which increases to 2.2 with inclusion of lower 
condom use in partnerships where HIV-diagnosed individuals assume their partner is HIV-
positive. 
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In contrast, higher and more commonly observed HCV ratios (>5) are achieved through 
including heterogeneity in sexual risk behaviour (scenario 4).  For instance, stratifying MSM 
in to low and high-risk groups based on the number of casual partners, with greater 
injecting drug use and fisting among high-risk individuals, and preferential mixing between 
these groups produces a HCV ratio of 9.7. 
Lastly, combining all behavioural and biological factors (scenario 5) amplifies the HCV ratio 
to 19.7, with different factors acting synergistically to transmit HCV amongst HIV-positive 
MSM but not HIV-negative MSM.  
 
Univariate and bivariate sensitivity analyses on the HCV ratio 
Univariate variations of parameters in scenario 5 around their point values (+/-100% - Table 
2) identified four key parameters that have most effect on the HCV ratio (figure 2): (1) 
proportion of individuals preferentially mixing by HIV status (HCV ratio varies from 9.7-
43.9); (2) error in HIV status judgements (HCV ratio varies 16.2-24.4); (3) ratio difference in 
numbers of partners between low and high-risk MSM groups (HCV ratio varies 3.4-28.6); 
and (4) additional relative risk for HCV transmission in high-risk MSM due to risky sexual 
behaviours (HCV ratio varies 8.3-33.5). Parameters that did not affect the HCV ratio as much 
are shown in Supplementary figure S3. 
The bivariate sensitivity analysis explored the relationship between the four most influential 
parameters from the univariate analysis (figure 3). The two risk heterogeneity parameters 
were varied simultaneously, forming one combined measure. The HCV ratio is sensitive to 
levels of heterogeneity in sexual risk behaviour and preferential mixing by HIV status, which 
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amplify each other. Indeed, the figures illustrate that HCV ratios of 5-20 are possible with 
high levels of risk heterogeneity alone, or moderate levels of both preferential mixing by HIV 
status and risk heterogeneity with any level of error in HIV status judgements. Greater error 
in HIV status judgements dampens the HCV ratio. 
Impact of HCV treatment-as-prevention 
Annually treating 10% of HIV-diagnosed HCV co-infected MSM for HCV over 10 years 
reduces HCV chronic prevalence among HIV-positive MSM by a relative 40.3-50.3% across 
the different scenarios (Figure 4a). However, impact among the entire MSM population 
varies markedly, from a relative reduction in chronic HCV among MSM of 3.5% for scenario 
1 to 29.3% for scenario 5 (Figure 4b). Figure 5 illustrates this effect further with the HCV 
ratio having a relatively small influence on the HCV treatment-as-prevention impact among 
HIV-positive MSM (Figure 5a), but a large influence amongst all MSM (Figure 5b). At higher 
HCV ratios, more of the epidemic is concentrated among HIV-positive MSM, so focussing 
treatment efforts on this population effectively combats the epidemic among all MSM. 
Univariate variations in parameters that have a large effect on the HCV ratio also affect the 
impact of HCV treatment amongst HIV-positive MSM on the overall HCV epidemic 
(supplementary figures S4 and S5).  
 
Discussion 
We find biological factors alone (lower spontaneous clearance rate and higher HCV 
infectivity and mortality amongst HIV-infected MSM) are unable to explain why the HCV 
epidemic is concentrated among HIV-positive MSM. Instead, we suggest that behavioural 
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factors (heterogeneity in sexual risk behaviour alone or combined with preferential mixing 
by HIV status) are highly likely to account for the higher HCV burdens among HIV-positive 
MSM.  Thus, HCV infection and co-infection should be seen as a marker of high sexual risk 
behaviours, which are preferentially undertaken within partnerships with other HIV-
positive MSM[12]. This is likely to have been aided by the scale-up of effective HIV 
treatment improving the survival of higher-risk MSM, paired with possible increases in risk 
behaviour due to ‘treatment optimism’[32].  
Importantly, these results highlight that changes in sexual behaviour or mixing patterns 
could reshape the HCV epidemic. For example, decreases in preferential mixing by HIV 
status could occur due to reductions in perceived risk resulting from widespread ART or 
PrEP use reducing HIV infectivity and susceptibility, which could increase HCV transmission 
amongst HIV-negative MSM. Alternatively, fewer high-risk MSM acquiring HIV (due to PrEP) 
may also raise the likelihood of HCV transmission among HIV-negative MSM, although this 
may be offset by increased HCV monitoring of MSM being prescribed PrEP. 
Further, HCV treatment-as-prevention initiatives among HIV-diagnosed MSM will have 
greatest impact on overall levels of HCV transmission in settings where HCV is concentrated 
among HIV-positive MSM, as less of the epidemic is driven by HIV-negative MSM. 
Conversely, settings which have, or develop, a greater burden of HCV among HIV-negative 
MSM would also need to focus HCV treatment to the HIV-negative MSM. 
Limitations 
Our analysis has a number of limitations. Firstly, we utilized a simplified model of HCV and 
HIV transmission and ART that was calibrated approximately to the UK without recreating 
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historical epidemic trends, which suggest a slowly increasing HIV and HCV epidemic[5, 30]. 
This was because our intention was to explore qualitatively how behavioural and biological 
factors contribute to HCV epidemic patterns, not make detailed predictions about the 
epidemics’ trajectory. Importantly, this simplification should not affect the degree to which 
HCV propagates preferentially amongst HIV-positive MSM. A further simplification of our 
model involved the incorporation of injecting drug use related risk as an increased 
transmission risk among a subset of MSM [6, 13-15], instead of explicitly modelling 
injecting. We made this simplification because, although injecting drug use is a risk factor 
for HIV/HCV acquisition amongst MSM, it is unclear the degree to which this is due to 
injecting drug use itself or co-occurring high-risk sexual behaviours. Also, datasets such as 
EMIS only ask basic questions about undertaking injecting drug use in the last year, so 
preventing any explicit modelling of its role in HCV transmission amongst MSM.   
Secondly, there exists uncertainty in our parameters and variation across settings, most 
notably amongst those related to self-reported behavioural data. We performed extensive 
sensitivity and scenario analyses to explore the effect of varying different behavioural 
factors. As such, our analyses form a platform from which to explore how variations in 
parameter assumptions effect observed epidemic patterns and treatment-as-prevention 
impact. However, care should be taken in generalising our results to non high-income 
settings where limited data suggests lower HCV-coinfection prevalences amongst MSM[33], 
and where differences in sexual behaviour and the underlying HIV and HCV epidemic are 
likely to heavily effect the HCV epidemic that occurs. 
Thirdly, although parameterizing our model to EMIS-UK data produced realistic projections 
for the HCV ratio (~20), we advise caution regarding potential over-interpretation of the 
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quantitative accuracy of our model. For instance, the model did not incorporate all sources 
of HCV infection, such as amongst migrants with historic HCV infection. Conversely, 
compared to a national probability survey on sexual behaviours, the EMIS-UK dataset used 
to parameterise our model was biased towards higher-risk MSM due to their web-based 
convenience sampling approach[34], as well as MSM with higher education levels[34]. These 
MSM may have a greater interest in HIV prevention and so increased propensity to mix 
preferentially by HIV status and use condoms with perceived sero-discordant partners.  
Finally, our estimate for increased HCV infectiousness amongst HIV-positive MSM is 
uncertain, although data from vertical transmission studies[11] suggests our assumption is 
reasonable. We assume that higher HCV viral load in blood samples amongst HIV-positive 
MSM translates to increased infectivity[10], but this may not be the case. However, this 
should not be a concern because this parameter had little effect on the resulting model 
projections. 
Comparison with other publications 
To our knowledge, this is the first modelling analysis of the joint epidemics of HIV and HCV 
among MSM, although many previous analyses have modelled just HIV[17] and some have 
also modelled other sexually transmitted infections (STI) among MSM[17, 35-38]. However, 
existing HIV and STI coinfection models generally considered different questions, focusing 
primarily on the degree to which STIs contribute to HIV transmission, and the possible 
impact of STI treatment on HIV epidemics. Previous analyses have also modelled the 
transmission of HIV and HCV amongst people who inject drugs [39-43]. Importantly, 
existing work by our group and others have modelled the HCV epidemic amongst HIV-
diagnosed MSM, and evaluated the impact of scaling-up HCV treatment in this group[5, 
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44]. These studies were limited in that they did not explicitly include HIV transmission. Our 
new analysis supports findings of these previous two studies by indicating that scaling-up 
HCV treatment among HIV-positive MSM could have substantial prevention benefits among 
HIV-positive MSM[16]. Additionally, it extends previous work by dynamically modelling the 
transmission of HCV to and from the HIV-negative population, assessing how different 
behavioural and biological factors could result in the observed epidemic patterns, and 
evaluating the implications for HCV treatment-as-prevention. 
Concluding remarks 
Overall, our work indicates that sexual risk behaviour heterogeneity and HIV preferential 
mixing likely explain why the HCV epidemic amongst MSM is strongly concentrated among 
HIV-positive MSM, with HCV co-infection possibly signifying high-risk behaviours as 
suggested by others[15]. Targeted HCV treatment-as-prevention amongst HIV-diagnosed 
MSM could be an important tool for combating the current HCV epidemic, but will have 
less impact in settings which have, or develop, a substantial burden of HCV among HIV-
negative MSM. This could occur if sexual risk behaviours increase amongst HIV-negative 
MSM or if higher-risk MSM do not become HIV-infected as frequently. This underscores the 
importance of monitoring HCV among HIV-negative MSM, to assess any shifts in the 
patterns of the HCV epidemic.  
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Figures 
 
Figure 1. Modelled HCV Ratio (ratio of HCV chronic prevalence among HIV-positive compared to 
HIV-negative MSM) for various scenarios incorporating different biological and/or behavioural 
factors as detailed in Table 2. *These scenarios also include the biological factors. IDU denotes 
injecting drug use.  
 
  
22 
 
Figure 2. Effect of univariate changes in individual parameters (A-D) on the HCV ratio for the “All 
effects” scenario 5. All other parameters are set to their point values in Table 2. Only those 
parameters that markedly affect the HCV ratio are shown. Numbers shown on x-axis are -100% of 
the point value, the point value and +100% of point value.  
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Figure 3. Contour maps showing how the HCV ratio (contour lines - produced by the “All effects” 
scenario 5) is affected by both the level of HIV preferential mixing (y axis) and sexual risk 
heterogeneity (x axis) for three levels of error in judging the HIV status of a sexual partner: (A) 
zero error (e=0%), (B) medium error (e=25%), (C) and high error (e=50%). All other parameters are 
set to their point values in Table 1. Sexual risk heterogeneity is the simultaneous variance of the 
ratio in the average number of partners between the low and high-risk groups and the additional 
relative risk for HCV transmission in high-risk MSM due to risky sexual behaviours, from -100% to 
+100% of their estimated point values, which vary respectively from 1 at -100% to 20.0 at +100% and 
1 at -100% to 5.4 at +100%. 
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Figure 4. Impact of HCV treatment on the relative reduction in HCV chronic prevalence (%) among 
(A) HIV-positive MSM and (B) all MSM, achieved by treating 10% of HIV-diagnosed MSM with HCV 
per year for 10 years. Projections assume the point value of parameters for each scenario in Table 1 
and assume 90% HCV treatment efficacy. *These scenarios also include the biological factors. 
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Figure 5. Effect of variations in the HCV ratio on the impact of HCV treatment-as-prevention (% 
relative reduction in chronic HCV prevalence at 10 years when treating at a rate of 10% of HIV 
diagnosed HCV co-infected MSM annually, y-axis) among (A) HIV-positive MSM, and (B) all MSM. 
We assume 90% HCV treatment efficacy, and uniformly sampled other parameters randomly 
between +/-100% of their point values.  
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Table 1: Model parameter values * See supplementary material for details
Parameter Value Source Details/Comments 
Inflow and outflow rate due to entry and exit (annual) 0.02 - Model age of sexual activity from 15-65 
Excess death rate due to chronic HCV mono-infection (annual) 0.0014  [45]  
Excess death rate due to mono-infection with HIV untreated (annual) 0.089 [25]  
Decreased mortality hazard ratio for HIV mono-infection due to ART 
treatment 
0.29 [25, 26]  
Excess death rate due to HIV in HIV-HCV co-infecteds with no HIV 
treatment* (annual) 
0.089 [25]  
Excess death rate due to HCV in HIV-HCV co-infecteds with no HIV 
treatment* (annual) 
0.0035 [28, 45] 2.5 times higher than the excess death 
rate in HCV mono-infected individuals. 
Excess death rate due to HCV in HIV-HCV co-infecteds with ART 
treatment* (annual) 
0.00238 [28, 45] 1.7  times higher than the excess death 
rate in HCV mono-infected individuals 
Transmission factor for HCV Fit [16] Model calibrated to a 10% chronic HCV 
prevalence among HIV-positive MSM 
Efficacy of HCV treatment 90% [31]  
Spontaneous clearance probability for HCV in HIV-negative MSM 0.25 [8]  
Odds ratio for spontaneous clearance probability for HCV in HIV-
positive MSM compared to HIV-negative MSM 
0.68 [9]  
 
Transmission factor for HIV Fit [30] Model calibrated to a 5% HIV prevalence 
among MSM 
Factor increase in HIV infectiousness during acute HIV phase compared 
to chronic HIV 
26 [22]  
Duration in months of acute HIV phase of infection 2.9  [22]  
Relative transmissibility of HIV infection when on ART treatment 
compared to untreated HIV 
0.1  [24, 46]   
Percentage of diagnosed MSM on ART treatment 83.2% [47]  
Diagnosis rate of HIV 1/3.2 yrs [30] Modelling approach to back calculate 
diagnosis rates for HIV, range for 2010. 
Factor increase in HCV infectiousness due to HIV co-infection 2.35 [10, 11] See supplementary material for details 
Percentage of MSM who mix non-randomly with MSM they assume 
have the same HIV status as them. Other MSM mix randomly. 
 35.2% EMIS See supplementary material for details 
Consistency of condom use between a HIV diagnosed MSM and an 
assumed HIV-positive partner in last sex act 
13% EMIS See supplementary material for details 
Consistency of condom use between all other MSM sexual pairings in 
last sex act 
68% EMIS See supplementary material for details 
Efficacy of condoms per sex act 70% [48]  
Chance of error when evaluating HIV status of a sexual partner* 24.9% EMIS See supplementary material for details 
Percentage of individuals in the low-risk sexual behaviour group* 82.2% EMIS EMIS data used to split the population 
into low and high-risk based on a 
number of casual partners for anal 
intercourse >15 or <15 in the last year. 
Percentage of individuals in the high-risk sexual behaviour group* 1-Low EMIS 
Mean number of casual sex partners for anal intercourse.  (When 
heterogeneity is turned on, low and high risk group in brackets)* 
7.4 [2.9, 
29.1] 
EMIS See supplementary material for details 
Increased overall risk ratio of HIV and HCV transmission due to injecting 
drugs and fisting between low and high risk group* 
2.7 EMIS   
[6, 13-15] 
See supplementary material for details 
Mixing parameter for choosing partners by risk behaviour category*  0.2 EMIS See supplementary material for details 
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Table 2: Parameterization of the scenarios with point values shown for each model. Sub-scenarios within the main scenarios take the 
parameter values corresponding to the values given by * and ** in the table where relevant. 
 
Scenario 
Description (*/** 
indicates values shown 
for different sub-
scenarios in figure 1 and 
5 and +/-100% values 
used in figure 3 and 6) 
HCV mono-
infection 
excess  
annual death 
rate 
Co-infection 
excess annual 
death rate 
without HAART 
Co-infection 
excess annual 
death rate on 
HAART 
RR for HCV 
infectivity 
if HIV+ 
compared 
to if HIV- 
High/low-
risk partner 
ratio 
High/low- 
risk 
fisting/IDU 
risk ratio 
Proportion 
MSM mixing 
by HIV Status 
Error in 
HIV-status 
judgement
s of sex 
partners 
High/low-risk 
condom use 
ratio 
Proportion 
MSM 
mixing by 
risk status 
RR of 
spontaneous 
clearance if 
HIV+ 
compared to 
HIV- 
1. Baseline 
 
No effects present 0 
0.089 (HIV 
related death 
rate) 
0.0258 (HIV 
related death 
rate) 
1 1 1 0 0 1 0 1 
2. Biological 
factors 
HCV death rates and HCV 
spontaneous clearance 
and infectivity are 
dependent on HIV status 
0.0014 0.0925 0.0282 
2.35 
[1, 3.7] 
1 1 0 0 1 0 
0.68 
[1, 0.36] 
3. Mixing by 
HIV status 
Biological factors with 
MSM preferentially 
selecting partners by HIV 
status, and sub-scenario 
with less condom use in 
assumed HIV+ pairings*  
plus error in judgements 
of HIV status 
0.0014 0.0925 0.0282 
2.35 
[1, 3.7] 
1 1 
35.2% 
[0%, 70.4%] 
24.9% 
 
1 or 5* 
[1, 9] 
0 
0.68 
[1, 0.36] 
4. Heteroge-
neity in 
sexual risk 
behaviour 
Biological factors with 
greater sexual partners 
amongst high-risk MSM. 
Sub-scenarios consider 
effects of MSM selecting 
partners based on risk 
behaviour and include 
risk from fisting or IDU** 
0.0014 0.0925 0.0282 
2.35 
[1, 3.7] 
1 or 10.0* 
[1, 20.0] 
1 or 2.7** 
[1, 4.4] 
0 0 1 
0.2 
[0, 0.4] 
0.68 
[1, 0.36] 
5. All effects 
All the effects from the 
other scenarios 
0.0014 0.0925 0.0282 
2.35 
[1, 3.7] 
10.0 
[1, 20.0] 
2.7 
[1, 4.4] 
35.2% 
[0%, 70.4%] 
24.9% 
[0%, 49.8%] 
5 
[1, 9] 
0.2 
[0, 0.4] 
0.68 
[1, 0.36] 
